Operationalizing and selecting outcome measures for the HEALing Communities Study

Svetla Slavova, Marc R LaRochelle, Elisabeth D Root, Daniel J Feaster, Jennifer Villani, Charles E Knott, Jeffery Talbert, Aimee Mack, Dushka Crane, Dana Bernson, Austin Booth, Sharon L Walsh, Svetla Slavova, Marc R LaRochelle, Elisabeth D Root, Daniel J Feaster, Jennifer Villani, Charles E Knott, Jeffery Talbert, Aimee Mack, Dushka Crane, Dana Bernson, Austin Booth, Sharon L Walsh

Abstract

Background: The Helping to End Addiction Long-termSM (HEALing) Communities Study (HCS) is a multisite, parallel-group, cluster randomized wait-list controlled trial evaluating the impact of the Communities That HEAL intervention to reduce opioid overdose deaths and associated adverse outcomes. This paper presents the approach used to define and align administrative data across the four research sites to measure key study outcomes.

Methods: Priority was given to using administrative data and established data collection infrastructure to ensure reliable, timely, and sustainable measures and to harmonize study outcomes across the HCS sites.

Results: The research teams established multiple data use agreements and developed technical specifications for more than 80 study measures. The primary outcome, number of opioid overdose deaths, will be measured from death certificate data. Three secondary outcome measures will support hypothesis testing for specific evidence-based practices known to decrease opioid overdose deaths: (1) number of naloxone units distributed in HCS communities; (2) number of unique HCS residents receiving Food and Drug Administration-approved buprenorphine products for treatment of opioid use disorder; and (3) number of HCS residents with new incidents of high-risk opioid prescribing.

Conclusions: The HCS has already made an impact on existing data capacity in the four states. In addition to providing data needed to measure study outcomes, the HCS will provide methodology and tools to facilitate data-driven responses to the opioid epidemic, and establish a central repository for community-level longitudinal data to help researchers and public health practitioners study and understand different aspects of the Communities That HEAL framework.

Trial registration: ClinicalTrials.gov NCT04111939.

Keywords: HEALing Communities Study; Helping to End Addiction Long-term(SM); High-risk prescribing; Naloxone; Opioid use disorder; Overdose.

Conflict of interest statement

The authors report no declarations of interest.

Copyright © 2020 Elsevier B.V. All rights reserved.

References

    1. Abouk R., Pacula R.L., Powell D. Association between state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose. JAMA Intern. Med. 2019;179:805–811. doi: 10.1001/jamainternmed.2019.0272.
    1. AcademyHealth . 2020. The Medicaid Outcomes Distributed Research Network (MODRN)
    1. Adams L., Kennedy S., Allen L., Barnes A., Bias T., Crane D., Lanier P., Mauk R., Mohamoud S., Pauly N., Talbert J., Woodcock C., Zivin K., Donohue J. Innovative solutions for state medicaid programs to leverage their data, build their analytic capacity, and create evidence-based policy. EGEMS (Wash DC) 2019;7:41. doi: 10.5334/egems.311.
    1. All-Payer Claims Database Council . 2009. Interactive State Report Map.
    1. Barocas J.A., White L.F., Wang J., Walley A.Y., LaRochelle M.R., Bernson D., Land T., Morgan J.R., Samet J.H., Linas B.P. Estimated prevalence of opioid use disorder in Massachusetts, 2011–2015: a capture-recapture analysis. Am. J. Publ. Health. 2018;108:1675–1681. doi: 10.2105/AJPH.2018.304673.
    1. Becker W.C., Fenton B.T., Brandt C.A., Doyle E.L., Francis J., Goulet J.L., Moore B.A., Torrise V., Kerns R.D., Kreiner P.W. Multiple sources of prescription payment and risky opioid therapy among veterans. Med. Care. 2017;55:S33–S36. doi: 10.1097/MLR.0000000000000722.
    1. Bohnert A.S., Valenstein M., Bair M.J., Ganoczy D., McCarthy J.F., Ilgen M.A., Blow F.C. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305:1315–1321. doi: 10.1001/jama.2011.370.
    1. Buchanich J.M., Balmert L.C., Williams K.E., Burke D.S. The effect of incomplete death certificates on estimates of unintentional opioid-related overdose deaths in the United States, 1999–2015. Publ. Health Rep. 2018;133:423–431. doi: 10.1177/0033354918774330.
    1. Burke L.G., Zhou X., Boyle K.L., Orav E.J., Bernson D., Hood M.E., Land T., Bharel M., Frakt A.B. Trends in opioid use disorder and overdose among opioid-naive individuals receiving an opioid prescription in Massachusetts from 2011 to 2014. Addiction. 2020;115:493–504. doi: 10.1111/add.14867.
    1. Centers for Disease Control and Prevention (CDC) U.S. Department of Health and Human Services. Centers for Disease Control and Prevention; Atlanta, GA: 2019. Annual Surveillance Report of Drug-Related Risks and Outcomes—United States, 2019. Surveillance Special Report.: Centers for Disease Control and Prevention.
    1. Centers for Disease Control and Prevention (CDC) 2019. Opioid Overdose. Data Resources. Analyzing Prescription Data and Morphine Milligram Equivalents (MME)
    1. Centers for Disease Control and Prevention (CDC) 2020. NCHS Data Quality Measures.
    1. Cochran G., Gordon A.J., Lo-Ciganic W.H., Gellad W.F., Frazier W., Lobo C., Chang C.H., Zheng P., Donohue J.M. An examination of claims-based predictors of overdose from a large Medicaid program. Med. Care. 2017;55:291–298. doi: 10.1097/MLR.0000000000000676.
    1. Commonwealth of Kentucky . Kentucky Cabinet for Health and Family Services, Office of Inspector General; Frankfort, KY: 2018. KASPER Controlled Substance Reporting Guide.
    1. CSTE . 2019. Council of State and Territorial Epidemiologists. Nonfatal Opioid Overdose Standardized Surveillance Case Definition. Available fromhttps:// 2019. Accessed Sept 12, 2020.
    1. Dowell D., Haegerich T.M., Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016;315:1624–1645. doi: 10.1001/jama.2016.1464.
    1. Dowell D., Haegerich T., Chou R. No shortcuts to safer opioid prescribing. N. Engl. J. Med. 2019;380:2285–2287. doi: 10.1056/NEJMp1904190.
    1. Dunn K.M., Saunders K.W., Rutter C.M., Banta-Green C.J., Merrill J.O., Sullivan M.D., Weisner C.M., Silverberg M.J., Campbell C.I., Psaty B.M., Von Korff M. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann. Intern. Med. 2010;152:85–92. doi: 10.7326/0003-4819-152-2-201001190-00006.
    1. e-CFR. Electronic Code of Federal Regulations . 2020. §2.16 Security for Records.
    1. e-CFR. Electronic Code of Federal Regulations . 2020. e-CFR Website.
    1. Freedman J.D., Green L., Landon B.E. All-payer claims databases - uses and expanded prospects after Gobeille. N. Engl. J. Med. 2016;375:2215–2217. doi: 10.1056/NEJMp1613276.
    1. Grecu A.M., Dave D.M., Saffer H. Mandatory access prescription drug monitoring programs and prescription drug abuse. J. Policy Anal. Manage. 2018;38:181–209. doi: 10.1002/pam.22098.
    1. Guy G.P., Jr., Zhang K., Bohm M.K., Losby J., Lewis B., Young R., Murphy L.B., Dowell D. Vital signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb. Mortal. Wkly. Rep. 2017;66:697–704. doi: 10.15585/mmwr.mm6626a4.
    1. Haffajee R.L., Lin L.A., Bohnert A.S.B., Goldstick J.E. Characteristics of US counties with high opioid overdose mortality and low capacity to deliver medications for opioid use disorder. JAMA Netw. Open. 2019;2:e196373. doi: 10.1001/jamanetworkopen.2019.6373.
    1. Hanzlick R. A perspective on medicolegal death investigation in the United States. Acad. Forensic Pathol. 2014;4:2–9.
    1. Hanzlick R., Combs D. Medical examiner and coroner systems: history and trends. JAMA. 1998;279:870–874. doi: 10.1001/jama.279.11.870.
    1. Hedegaard H., Miniño A., Warner M. National Center for Health Statistics; Hyattsville, MD: 2020. Drug Overdose Deaths in the United States, 1999–2018.
    1. Injury Surveillance Workgroup 7 (ISW7) 2012. Consensus Recommendations for National and State Poisoning Surveillance.
    1. Joudrey P.J., Edelman E.J., Wang E.A. Drive times to opioid treatment programs in urban and rural counties in 5 US States. JAMA. 2019;322:1310–1312. doi: 10.1001/jama.2019.12562.
    1. Krawczyk N., Picher C.E., Feder K.A., Saloner B. Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine. Health Aff. (Millwood) 2017;36:2046–2053. doi: 10.1377/hlthaff.2017.0890.
    1. Krupitsky E., Nunes E.V., Ling W., Illeperuma A., Gastfriend D.R., Silverman B.L. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377:1506–1513. doi: 10.1016/s0140-6736(11)60358-9.
    1. Larochelle M.R., Bernson D., Land T., Stopka T.J., Wang N., Xuan Z., Bagley S.M., Liebschutz J.M., Walley A.Y. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann. Intern. Med. 2018;169:137–145. doi: 10.7326/M17-3107.
    1. LeBaron V.T., Camacho F., Balkrishnan R., Yao N.A., Gilson A.M. Opioid epidemic or pain crisis? Using the Virginia all payer claims database to describe opioid medication prescribing patterns and potential harms for patients with cancer. J. Oncol. Pract. 2019;15:e997–e1009. doi: 10.1200/JOP.19.00149.
    1. Lefebvre R.C., Chandler R.K., Helme D.W., Kerner R., Mann S., Stein M.D., Reynolds J., Slater M.D., Anakaraonye A.R., Beard D., Burrus O., Frkovich J., Hedrick H., Lewis N., Rodgers E. Health communication campaigns to drive demand for evidence-based practices and reduce stigma in the HEALing Communities Study. Drug Alcohol Depend. 2020;217:108338. doi: 10.1016/j.drugalcdep.2020.108338.
    1. Sprague Martinez L., Rapkin B.D., Young A., Freisthler B., Glasgow L., Hunt T., Salsberry P., Oga E.A., Bennet-Fallin A., Plouck T.J., Drainoni M.-L., Freeman P.R., Surratt H., Gulley J., Hamilton G.A., Bowman P., Roeber C.A., El-Bassel N., Battaglia T. Community engagement to implement evidence-based practices in the HEALing Communities Study. Drug Alcohol Depend. 2020;217:108326. doi: 10.1016/j.drugalcdep.2020.108326.
    1. . 2020. Pharmacy Reporting and Data Submission.
    1. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst. Rev. 2009:CD002209. doi: 10.1002/14651858.CD002209.pub2.
    1. Mattick R.P., Breen C., Kimber J., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. 2014:CD002207. doi: 10.1002/14651858.CD002207.pub4.
    1. Miller M., Barber C.W., Leatherman S., Fonda J., Hermos J.A., Cho K., Gagnon D.R. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern. Med. 2015;175:608–615. doi: 10.1001/jamainternmed.2014.8071.
    1. National Center for Health Statistics (NCHS) National Center for Health Statistics; Hyattsville, MD: 2003. Medical Examiners’ and Coroners’ Handbook on Death Registration and Fetal Death Reporting, 2003 Revision.
    1. National Center for Health Statistics (NCHS) National Center for Health Statistics; Hyattsville, MD: 2003. U.S. Standard Certificate of Death, 2003 Revision.
    1. New York Department of Health . 2019. Electronic Data Transmission. Accessed on July 14, 2020.
    1. Ohio Automated RX Reporting System . 2017. Ohio Data Submission Dispenser Guide.
    1. Pashmineh Azar A.R., Cruz-Mullane A., Podd J.C., Lam W.S., Kaleem S.H., Lockard L.B., Mandel M.R., Chung D.Y., Simoyan O.M., Davis C.S., Nichols S.D., McCall K.L., Piper B.J. Rise and regional disparities in buprenorphine utilization in the United States. Pharmacoepidemiol. Drug Saf. 2020;29:708–715. doi: 10.1002/pds.4984.
    1. Prescription Drug Monitoring Program Training and Technical Assistance Center (PDMP TTAC) 2018. History of Prescription Drug Monitoring Programs.
    1. Prescription Drug Monitoring Program Training and Technical Assistance Center (PDMP TTAC) 2020. PDMP Policies and Practices.
    1. Rose A.J., Bernson D., Chui K.K.H., Land T., Walley A.Y., LaRochelle M.R., Stein B.D., Stopka T.J. Potentially inappropriate opioid prescribing, overdose, and mortality in Massachusetts, 2011–2015. J. Gen. Intern. Med. 2018;33:1512–1519. doi: 10.1007/s11606-018-4532-5.
    1. Rossen L., Ahmad F., Spencer M., Warner M., Sutton P. National Center for Health Statistics, Centers for Disease Control and Prevention; Atlanta, GA: 2017. Method to Adjust Provisional Counts of Drug Overdose Deaths for Underreporting. Division of Vital Statistics.
    1. Ruhm C.J. Corrected US opioid-involved drug poisoning deaths and mortality rates, 1999–2015. Addiction. 2018;113:1339–1344. doi: 10.1111/add.14144.
    1. Saloner B., Daubresse M., Caleb Alexander G. Patterns of buprenorphine-naloxone treatment for opioid use disorder in a multistate population. Med. Care. 2017;55:669–676. doi: 10.1097/mlr.0000000000000727.
    1. Schieber L.Z., Guy G.P., Jr., Seth P., Losby J.L. Variation in adult outpatient opioid prescription dispensing by age and sex – United States, 2008–2018. MMWR Morb. Mortal. Wkly. Rep. 2020;69:298–302. doi: 10.15585/mmwr.mm6911a5.
    1. Scholl L., Seth P., Kariisa M., Wilson N., Baldwin G. Drug and opioid-involved overdose deaths – United States, 2013–2017. MMWR Morb. Mortal. Wkly. Rep. 2018;67:1419–1427. doi: 10.15585/mmwr.mm675152e1.
    1. Shah A., Hayes C.J., Martin B.C. Characteristics of initial prescription episodes and likelihood of long-term opioid use – United States, 2006–2015. MMWR Morb. Mortal. Wkly. Rep. 2017;66:265–269. doi: 10.15585/mmwr.mm6610a1.
    1. Slavova S., O’Brien D.B., Creppage K., Dao D., Fondario A., Haile E., Hume B., Largo T.W., Nguyen C., Sabel J.C., Wright D. Drug overdose deaths: let’s get specific. Publ. Health Rep. (Washington, D.C.: 1974) 2015;130:339–342.
    1. Slavova S., Delcher C., Buchanich J.M., Bunn T.L., Goldberger B.A., Costich J.F. Methodological complexities in quantifying rates of fatal opioid-related overdose. Curr. Epidemiol. Rep. 2019;6:263–274. doi: 10.1007/s40471-019-00201-9.
    1. Sordo L., Barrio G., Bravo M.J., Indave B.I., Degenhardt L., Wiessing L., Ferri M., Pastor-Barriuso R. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ (Clin. Ed.) 2017;357:j1550. doi: 10.1136/bmj.j1550.
    1. Substance Abuse Mental Health Services Administration (SAMHSA) SAMSHA; Rockville, MD: 2018. Medications for Opioid Use Disorder, Treatment Improvement Protocol (TIP) Series, No 63.
    1. Substance Abuse Mental Health Services Administration (SAMHSA) 2020. Certification of Opioid Treatment Programs (OTPs)
    1. The HEALing Communities Study Consortium HEALing (Helping to End Addiction Long-term) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an Integrated set of evidence-based practices. Drug Alcohol Depend. 2020;217:108335. doi: 10.1016/j.drugalcdep.2020.108335.
    1. U.S. Department of Health and Human Services (HHS) 2018. US Surgeon General’s Advisory on Naloxone and Opioid Overdose.
    1. U.S. Department of Health and Human Services (HHS) 2019. HHS Guide for Clinicians on the Appropriate Dosage Reduction or Discontinuation of Long-term Opioid Analgesics.
    1. U.S. Food and Drug Administration (FDA) 2019. FDA Identifies Harm Reported From Sudden Discontinuation of Opioid Pain Medicines and Requires Label Changes to Guide Prescribers on Gradual, Individualized Tapering. Accessed on July 14, 2020.
    1. Walley A.Y., Xuan Z., Hackman H.H., Quinn E., Doe-Simkins M., Sorensen-Alawad A., Ruiz S., Ozonoff A. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174. doi: 10.1136/bmj.f174.
    1. Warner M., Hedegaard H. Identifying opioid overdose deaths using vital statistics data. Am. J. Publ. Health. 2018;108:1587–1589.
    1. Warner M., Paulozzi L., Nolte K., Davis G., Nelson L. State variation in certifying manner of death and drugs involved in drug intoxication deaths. Acad. Forensic Pathol. 2013;3:231–237.
    1. Winhusen T., Walley A., Fanucchi L.C., Hunt T., Lyons M., Lofwall M., Brown J.L., Freeman P.R., Nunes E., Beers D., Saitz R., Stambaugh L., Oga E.A., Herron N., Baker T., Cook C.D., Roberts M.F., Alford D.P., Starrels J.L., Chandler R.K. The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study. Drug Alcohol Depend. 2020;217:108325. doi: 10.1016/j.drugalcdep.2020.108325.
    1. Wolters Kluwer . 2020. Drug Data. Accessed on July 14, 2020.
    1. World Health Organization (WHO) 2016. ICD-10 Version: 2016.
    1. Wu E., Villani J., Davis A., Fareed N., Harris D.R., Huerta T.R., LaRochelle M.R., Miller C.C., Oga E.A. Community dashboards to support data-informed decision-making in the HEALing Communities Study. Drug Alcohol Depend. 2020;217:108331. doi: 10.1016/j.drugalcdep.2020.108331.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi